


## (Ala13)-Apelin-13 TFA

<b>Cat. No.:</b>	HY-P3162A
<b>Molecular Formula:</b>	C <sub>63</sub> H <sub>107</sub> N <sub>23</sub> O <sub>16</sub> S.xC <sub>2</sub> HF <sub>3</sub> O <sub>2</sub>
<b>Target:</b>	Apelin Receptor (APJ)
<b>Pathway:</b>	GPCR/G Protein
<b>Storage:</b>	Sealed storage, away from moisture and light
	Powder    -80°C    2 years
	-20°C    1 year
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	H <sub>2</sub> O : 100 mg/mL (Need ultrasonic)
-----------------	--

### BIOLOGICAL ACTIVITY

<b>Description</b>	(Ala13)-Apelin-13 TFA is a potent apelin receptors (APJ) antagonist. (Ala13)-Apelin-13 TFA inhibits gastric motility through vagal cholinergic pathway <sup>[1]</sup> .
<b>In Vivo</b>	(Ala13)-Apelin-13 TFA (1-300 pmol/60 nL; microinjected into the DVC) decreases gastric tone and motility in a dose-dependent manner in rats <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Bülbül M, et al. Apelin-13 inhibits gastric motility through vagal cholinergic pathway in rats. *Am J Physiol Gastrointest Liver Physiol*. 2018 Feb 1;314(2):G201-G210.
- [2]. O'Harte FPM, et al. Acylated apelin-13 amide analogues exhibit enzyme resistance and prolonged insulin releasing, glucose lowering and anorexic properties. *Biochem Pharmacol*. 2017 Dec 15;146:165-173.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA